The association of plasma cystatin C proteoforms with diabetic chronic kidney disease

Hussein N. Yassine, Olgica Trenchevska, Zhiwei Dong, Yara Bashawri, Juraj Koska, Peter D. Reaven, Randall W. Nelson, Dobrin Nedelkov

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Cystatin C (CysC) is an endogenous cysteine protease inhibitor that can be used to assess the progression of kidney function. Recent studies demonstrate that CysC is a more specific indicator of glomerular filtration rate (GFR) than creatinine. CysC in plasma exists in multiple proteoforms. The goal of this study was to clarify the association of native CysC, CysC missing N-terminal Serine (CysC des-S), and CysC without three N-terminal residues (CysC des-SSP) with diabetic chronic kidney disease (CKD). Results: Using mass spectrometric immunoassay, the plasma concentrations of native CysC and the two CysC truncation proteoforms were examined in 111 individuals from three groups: 33 non-diabetic controls, 34 participants with type 2 diabetes (DM) and without CKD and 44 participants with diabetic CKD. Native CysC concentrations were 1.4 fold greater in CKD compared to DM group (p = 0.02) and 1.5 fold greater in CKD compared to the control group (p = 0.001). CysC des-S concentrations were 1.55 fold greater in CKD compared to the DM group (p = 0.002) and 1.9 fold greater in CKD compared to the control group (p = 0.0002). CysC des-SSP concentrations were 1.8 fold greater in CKD compared to the DM group (p = 0.008) and 1.52 fold greater in CKD compared to the control group (p = 0.002). In addition, the concentrations of CysC proteoforms were greater in the setting of albuminuria. The truncated CysC proteoform concentrations were associated with estimated GFR independent of native CysC concentrations. Conclusion: Our findings demonstrate a greater amount of CysC proteoforms in diabetic CKD. We therefore suggest assessing the role of cystatin C proteoforms in the progression of CKD.

Original languageEnglish (US)
Article number7
JournalProteome Science
Volume14
Issue number1
DOIs
StatePublished - Mar 25 2016

Fingerprint

Cystatin C
Diabetic Nephropathies
Chronic Renal Insufficiency
Plasmas
Glomerular Filtration Rate
Control Groups
Cysteine Proteinase Inhibitors
Albuminuria

Keywords

  • Chronic kidney disease
  • Cystatin C
  • Mass spectrometry
  • Truncations

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Yassine, H. N., Trenchevska, O., Dong, Z., Bashawri, Y., Koska, J., Reaven, P. D., ... Nedelkov, D. (2016). The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. Proteome Science, 14(1), [7]. https://doi.org/10.1186/s12953-016-0096-7

The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. / Yassine, Hussein N.; Trenchevska, Olgica; Dong, Zhiwei; Bashawri, Yara; Koska, Juraj; Reaven, Peter D.; Nelson, Randall W.; Nedelkov, Dobrin.

In: Proteome Science, Vol. 14, No. 1, 7, 25.03.2016.

Research output: Contribution to journalArticle

Yassine, HN, Trenchevska, O, Dong, Z, Bashawri, Y, Koska, J, Reaven, PD, Nelson, RW & Nedelkov, D 2016, 'The association of plasma cystatin C proteoforms with diabetic chronic kidney disease', Proteome Science, vol. 14, no. 1, 7. https://doi.org/10.1186/s12953-016-0096-7
Yassine HN, Trenchevska O, Dong Z, Bashawri Y, Koska J, Reaven PD et al. The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. Proteome Science. 2016 Mar 25;14(1). 7. https://doi.org/10.1186/s12953-016-0096-7
Yassine, Hussein N. ; Trenchevska, Olgica ; Dong, Zhiwei ; Bashawri, Yara ; Koska, Juraj ; Reaven, Peter D. ; Nelson, Randall W. ; Nedelkov, Dobrin. / The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. In: Proteome Science. 2016 ; Vol. 14, No. 1.
@article{0cfac0ff40c844a5a7713f5aff923828,
title = "The association of plasma cystatin C proteoforms with diabetic chronic kidney disease",
abstract = "Background: Cystatin C (CysC) is an endogenous cysteine protease inhibitor that can be used to assess the progression of kidney function. Recent studies demonstrate that CysC is a more specific indicator of glomerular filtration rate (GFR) than creatinine. CysC in plasma exists in multiple proteoforms. The goal of this study was to clarify the association of native CysC, CysC missing N-terminal Serine (CysC des-S), and CysC without three N-terminal residues (CysC des-SSP) with diabetic chronic kidney disease (CKD). Results: Using mass spectrometric immunoassay, the plasma concentrations of native CysC and the two CysC truncation proteoforms were examined in 111 individuals from three groups: 33 non-diabetic controls, 34 participants with type 2 diabetes (DM) and without CKD and 44 participants with diabetic CKD. Native CysC concentrations were 1.4 fold greater in CKD compared to DM group (p = 0.02) and 1.5 fold greater in CKD compared to the control group (p = 0.001). CysC des-S concentrations were 1.55 fold greater in CKD compared to the DM group (p = 0.002) and 1.9 fold greater in CKD compared to the control group (p = 0.0002). CysC des-SSP concentrations were 1.8 fold greater in CKD compared to the DM group (p = 0.008) and 1.52 fold greater in CKD compared to the control group (p = 0.002). In addition, the concentrations of CysC proteoforms were greater in the setting of albuminuria. The truncated CysC proteoform concentrations were associated with estimated GFR independent of native CysC concentrations. Conclusion: Our findings demonstrate a greater amount of CysC proteoforms in diabetic CKD. We therefore suggest assessing the role of cystatin C proteoforms in the progression of CKD.",
keywords = "Chronic kidney disease, Cystatin C, Mass spectrometry, Truncations",
author = "Yassine, {Hussein N.} and Olgica Trenchevska and Zhiwei Dong and Yara Bashawri and Juraj Koska and Reaven, {Peter D.} and Nelson, {Randall W.} and Dobrin Nedelkov",
year = "2016",
month = "3",
day = "25",
doi = "10.1186/s12953-016-0096-7",
language = "English (US)",
volume = "14",
journal = "Proteome Science",
issn = "1477-5956",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The association of plasma cystatin C proteoforms with diabetic chronic kidney disease

AU - Yassine, Hussein N.

AU - Trenchevska, Olgica

AU - Dong, Zhiwei

AU - Bashawri, Yara

AU - Koska, Juraj

AU - Reaven, Peter D.

AU - Nelson, Randall W.

AU - Nedelkov, Dobrin

PY - 2016/3/25

Y1 - 2016/3/25

N2 - Background: Cystatin C (CysC) is an endogenous cysteine protease inhibitor that can be used to assess the progression of kidney function. Recent studies demonstrate that CysC is a more specific indicator of glomerular filtration rate (GFR) than creatinine. CysC in plasma exists in multiple proteoforms. The goal of this study was to clarify the association of native CysC, CysC missing N-terminal Serine (CysC des-S), and CysC without three N-terminal residues (CysC des-SSP) with diabetic chronic kidney disease (CKD). Results: Using mass spectrometric immunoassay, the plasma concentrations of native CysC and the two CysC truncation proteoforms were examined in 111 individuals from three groups: 33 non-diabetic controls, 34 participants with type 2 diabetes (DM) and without CKD and 44 participants with diabetic CKD. Native CysC concentrations were 1.4 fold greater in CKD compared to DM group (p = 0.02) and 1.5 fold greater in CKD compared to the control group (p = 0.001). CysC des-S concentrations were 1.55 fold greater in CKD compared to the DM group (p = 0.002) and 1.9 fold greater in CKD compared to the control group (p = 0.0002). CysC des-SSP concentrations were 1.8 fold greater in CKD compared to the DM group (p = 0.008) and 1.52 fold greater in CKD compared to the control group (p = 0.002). In addition, the concentrations of CysC proteoforms were greater in the setting of albuminuria. The truncated CysC proteoform concentrations were associated with estimated GFR independent of native CysC concentrations. Conclusion: Our findings demonstrate a greater amount of CysC proteoforms in diabetic CKD. We therefore suggest assessing the role of cystatin C proteoforms in the progression of CKD.

AB - Background: Cystatin C (CysC) is an endogenous cysteine protease inhibitor that can be used to assess the progression of kidney function. Recent studies demonstrate that CysC is a more specific indicator of glomerular filtration rate (GFR) than creatinine. CysC in plasma exists in multiple proteoforms. The goal of this study was to clarify the association of native CysC, CysC missing N-terminal Serine (CysC des-S), and CysC without three N-terminal residues (CysC des-SSP) with diabetic chronic kidney disease (CKD). Results: Using mass spectrometric immunoassay, the plasma concentrations of native CysC and the two CysC truncation proteoforms were examined in 111 individuals from three groups: 33 non-diabetic controls, 34 participants with type 2 diabetes (DM) and without CKD and 44 participants with diabetic CKD. Native CysC concentrations were 1.4 fold greater in CKD compared to DM group (p = 0.02) and 1.5 fold greater in CKD compared to the control group (p = 0.001). CysC des-S concentrations were 1.55 fold greater in CKD compared to the DM group (p = 0.002) and 1.9 fold greater in CKD compared to the control group (p = 0.0002). CysC des-SSP concentrations were 1.8 fold greater in CKD compared to the DM group (p = 0.008) and 1.52 fold greater in CKD compared to the control group (p = 0.002). In addition, the concentrations of CysC proteoforms were greater in the setting of albuminuria. The truncated CysC proteoform concentrations were associated with estimated GFR independent of native CysC concentrations. Conclusion: Our findings demonstrate a greater amount of CysC proteoforms in diabetic CKD. We therefore suggest assessing the role of cystatin C proteoforms in the progression of CKD.

KW - Chronic kidney disease

KW - Cystatin C

KW - Mass spectrometry

KW - Truncations

UR - http://www.scopus.com/inward/record.url?scp=84961619672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961619672&partnerID=8YFLogxK

U2 - 10.1186/s12953-016-0096-7

DO - 10.1186/s12953-016-0096-7

M3 - Article

AN - SCOPUS:84961619672

VL - 14

JO - Proteome Science

JF - Proteome Science

SN - 1477-5956

IS - 1

M1 - 7

ER -